Recent developments

at Tullis and our portfolio companies

News

Keeping you current on new and follow-on investments, portfolio product and service milestones, publications and events, management and board transitions, and other developments in Tullis funds.

November

13

Exagen Inc. Reports Strong Third Quarter 2023 Results

SAN DIEGO, California, Nov. 13, 2023 (GLOBE NEWSWIRE) — Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune...

9

Exagen Inc. and Johns Hopkins University Announce License Agreement for Novel Patented Lupus Nephritis Biomarkers

SAN DIEGO, California, Nov. 09, 2023 (GLOBE NEWSWIRE) — Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune...

7

Exagen Inc. Reports Strong Second Quarter 2023 Results

SAN DIEGO, Aug. 07, 2023 (GLOBE NEWSWIRE) — Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing...

24

Exagen Inc. Appoints Paul Kim to Board of Directors

SAN DIEGO, July 24, 2023 (GLOBE NEWSWIRE) — Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing...

15

Exagen Inc. Reports First Quarter 2023 Results

Record Physician Demand for AVISE® CTD SAN DIEGO, May 15, 2023 (GLOBE NEWSWIRE) — Exagen Inc. (Nasdaq: XGN)(“Exagen”), a...

20

Exagen Inc. Reports Fourth Quarter and Full Year 2022 Results

Record AVISE® CTD Volume in 2022 SAN DIEGO, March 20, 2023 (GLOBE NEWSWIRE) — Exagen Inc. (Nasdaq: XGN), a...

23

Exagen Inc. Elects Tina S. Nova, Ph.D. as Executive Chair of the Board of Directors

SAN DIEGO, Jan. 23, 2023 (GLOBE NEWSWIRE) — Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions,...

14

Exagen Inc. Reports Third Quarter 2022 Results

Medicare Reimbursement Returns SAN DIEGO, Nov. 14, 2022 (GLOBE NEWSWIRE) — Exagen Inc. (Nasdaq: XGN), a leading provider of...

4

Exagen Announces Appointment of Andrew L. Concoff MD, FACR, CAQSM, as Chief Innovation Officer

Dr. Concoff to lead rheumatoid arthritis medical initiatives SAN DIEGO, Oct. 04, 2022 (GLOBE NEWSWIRE) —...

1

Exagen Collaboration Leads to Characterization of Broad Autoreactivity in Severe COVID-19 Patients

SAN DIEGO, Sept. 01, 2022 (GLOBE NEWSWIRE) — Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing...

5

Exagen Releases Largest Comparative Utility Study in Lupus Diagnostics Confirming AVISE® Lupus Delivers Unparalleled Utility

AVISE® Lupus more clinically effective than current standard of care SAN DIEGO, July 05, 2022 (GLOBE...

9

Exagen Inc. Expands Coverage with MediNcrease

SAN DIEGO, June 09, 2022 (GLOBE NEWSWIRE) — Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing...

Recent developments

News

November

13

Exagen Inc. Reports Strong Third Quarter 2023 Results

November

9

Exagen Inc. and Johns Hopkins University Announce License Agreement for Novel Patented Lupus Nephritis Biomarkers

August

7

Exagen Inc. Reports Strong Second Quarter 2023 Results

July

24

Exagen Inc. Appoints Paul Kim to Board of Directors

May

15

Exagen Inc. Reports First Quarter 2023 Results

March

20

Exagen Inc. Reports Fourth Quarter and Full Year 2022 Results

January

23

Exagen Inc. Elects Tina S. Nova, Ph.D. as Executive Chair of the Board of Directors

November

14

Exagen Inc. Reports Third Quarter 2022 Results

October

4

Exagen Announces Appointment of Andrew L. Concoff MD, FACR, CAQSM, as Chief Innovation Officer

September

1

Exagen Collaboration Leads to Characterization of Broad Autoreactivity in Severe COVID-19 Patients

July

5

Exagen Releases Largest Comparative Utility Study in Lupus Diagnostics Confirming AVISE® Lupus Delivers Unparalleled Utility

June

9

Exagen Inc. Expands Coverage with MediNcrease